- Home
- KZIA vs EVOK Comparison
KZIA vs EVOK Comparison
Compare KZIA & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- EVOK
- Stock Information
- Founded
- KZIA 1994
- EVOK 2007
- Country
- KZIA Australia
- EVOK United States
- Employees
- KZIA N/A
- EVOK 4
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- EVOK Health Care
- Exchange
- KZIA Nasdaq
- EVOK Nasdaq
- Market Cap
- KZIA 7.8M
- EVOK 7.1M
- IPO Year
- KZIA 1999
- EVOK 2013
- Fundamental
- Price
- KZIA $1.29
- EVOK $4.81
- Analyst Decision
- KZIA Strong Buy
- EVOK
- Analyst Count
- KZIA 2
- EVOK 0
- Target Price
- KZIA $11.50
- EVOK N/A
- AVG Volume (30 Days)
- KZIA 5.4M
- EVOK 9.9K
- Earning Date
- KZIA 03-26-2025
- EVOK 03-13-2025
- Dividend Yield
- KZIA N/A
- EVOK N/A
- EPS Growth
- KZIA N/A
- EVOK N/A
- EPS
- KZIA N/A
- EVOK N/A
- Revenue
- KZIA $1,655,324.00
- EVOK $8,617,036.00
- Revenue This Year
- KZIA $806.89
- EVOK $97.35
- Revenue Next Year
- KZIA N/A
- EVOK $99.52
- P/E Ratio
- KZIA N/A
- EVOK N/A
- Revenue Growth
- KZIA 248000.00
- EVOK 100.35
- 52 Week Low
- KZIA $1.31
- EVOK $3.54
- 52 Week High
- KZIA $15.80
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- KZIA 39.50
- EVOK 59.77
- Support Level
- KZIA $1.31
- EVOK $4.68
- Resistance Level
- KZIA $2.64
- EVOK $4.94
- Average True Range (ATR)
- KZIA 0.24
- EVOK 0.28
- MACD
- KZIA 0.09
- EVOK 0.06
- Stochastic Oscillator
- KZIA 14.29
- EVOK 73.58
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.